Collegium PharmaceuticalFRA:354 75 EBITDA Margin % is 46.78% as of Mar. 2026, which is 33% above its 10-year median of 35.07. GuruFocus rates FRA:354 with a GF Score™ of 75/100 and a GF Value™ of €37.18 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 954 Drug Manufacturers companies, Collegium Pharmaceutical ranks better than 96.75% on this metric.
Collegium Pharmaceutical (FRA:354) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Collegium Pharmaceutical EBITDA Margin % Related Terms
Collegium Pharmaceutical EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:354 vs ALVO, PAHC, BIOA: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Collegium Pharmaceutical's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Collegium Pharmaceutical EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Collegium Pharmaceutical's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Collegium Pharmaceutical's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Collegium Pharmaceutical (FRA:354) has a EBITDA Margin % of 46.78% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Collegium Pharmaceutical and its competitors. This is 33% above median its historical median of 35.07. According to the industry distribution chart, Collegium Pharmaceutical ranks #31 out of 954 companies in the Drug Manufacturers industry, placing it in the top 3.2%.
Is Collegium Pharmaceutical's EBITDA Margin % too high?
Collegium Pharmaceutical's current EBITDA Margin % of 46.78% is 33% above median its 10-year median of 35.07. The Drug Manufacturers industry median EBITDA Margin % is 12.52. Collegium Pharmaceutical's value of 46.78% is 273.8% above this industry median. Based on the distribution chart, Collegium Pharmaceutical ranks #31 out of 954 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Collegium Pharmaceutical has a GF Score™ of 75/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Collegium Pharmaceutical's EBITDA Margin % compare to ALVO and PAHC?
According to the Drug Manufacturers industry distribution chart, Collegium Pharmaceutical ranks #31 out of 954 companies for EBITDA Margin %. This places Collegium Pharmaceutical in the top 3% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 12.52. Collegium Pharmaceutical's value of 46.78% is 273.8% above this benchmark. While the company's 10-year median is 35.07 vs. the industry median of 12.52, Collegium Pharmaceutical has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.52, based on 954 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Collegium Pharmaceutical's current EBITDA Margin % of 46.78% is 273.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Collegium Pharmaceutical and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Collegium Pharmaceutical's current EBITDA Margin % is 46.78%, which is 33% above median its own 10-year median of 35.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Collegium Pharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, Collegium Pharmaceutical (FRA:354) is currently considered Modestly Undervalued. The stock's GF Value™ is €37.18, compared to a current price of €31.20 — trading 16.1% below its estimated fair value. The current EBITDA Margin % is 46.78%, which is 33% above median its 10-year median of 35.07 and 273.8% above the Drug Manufacturers industry median of 12.52. Collegium Pharmaceutical's overall GF Score™ is 75/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Collegium Pharmaceutical (FRA:354), the current EBITDA Margin % is 46.78% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Collegium Pharmaceutical (FRA:354) Overvalued in 2026?
Based on GuruFocus' analysis, Collegium Pharmaceutical stock appears to be undervalued.
The current stock price of €31.20 is trading 16.1% below its estimated GF Value™ of €37.18.
GuruFocus considers Collegium Pharmaceutical to be Modestly Undervalued.
Key valuation signals for FRA:354:
EBITDA Margin %: 46.78% (33% above median its 10-year median of 35.07)
GF Value™: €37.18 vs. price of €31.20 (16.1% below fair value)
Industry Position: 273.8% above the Drug Manufacturers median (#31 of 954)
No single metric tells the full story. See the FRA:354 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.
75GF Score
Get the complete analysis for FRA:354
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:354 has been successfully added to your 
